Marla Weetall
Seminars
Wednesday 7th October 2026
Translational Pharmacology & Biomarker Strategy in Drug Discovery & Development
5:30 pm
- Approval of a drug requires a statistically significant improvement in an outcome measure. Outcome measures, reflecting how patients feels or function, can require many patients and long studies to reach statistical significance
- Biomarkers, object measures of biological changes, can be used to select the dose and to provide evidence of disease modulation with fewer patients and in less time
- Preclinical studies can be utilized to link a biomarker to subsequent outcome measures
